NAV
$92.15
AUM
$259.0M
Expense Ratio
-
Dividend Yield
0.62%
Beta
0.81
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +12.08% | +10.29% | +16.77% | +42.68% | +15.54% | +4.03% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ILMN | Illumina Inc | 6.55% |
| 2 | UTHR | United Therapeutics Corp | 5.81% |
| 3 | BIIB | Biogen Inc | 4.96% |
| 4 | INCY | Incyte Corp | 4.73% |
| 5 | GILD | Gilead Sciences Inc | 4.50% |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | 4.48% |
| 7 | AMGN | Amgen Inc | 4.34% |
| 8 | REGN | Regeneron Pharmaceuticals Inc | 3.93% |
| 9 | VCYT | Veracyte Inc | 3.50% |
| 10 | CPRX | Catalyst Pharmaceuticals Inc | 3.48% |
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Inception Date: 2005-06-23